Latin America Liquid Biopsy Market Analysis and Forecast 2019-2025

Latin America Liquid
Biopsy Market
Focus on Products and Services,
Therapeutic Applications, Clinical
Applications, Circulating Biomarkers,
5 Countries Data, Industry Insights,
and Competitive Landscape –
Analysis and Forecast, 2019-2025
March 2019

Latin America Liquid Biopsy Market
All rights reserved at BIS Research 1
BIS Research is a leading market intelligence and technology research company. BIS Research
publishes in-depth market intelligence reports focusing on the market estimations, technology
analysis, emerging high-growth applications, deeply segmented granular country-level market data
and other important market parameters useful in the strategic decision making for senior
management. BIS Research provides multi-client reports, company profiles, databases, and custom
research services.
Copyright © 2019 BIS Research
All Rights Reserved. This document contains highly confidential information and is the sole property
of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all
contents of this document is strictly prohibited. Access to this information is provided exclusively for
the benefit of the people or the organization concerned. It may not be accessed by or offered to,
whether for sale or otherwise, any third party.

Click Here to Nominate Yourself or
Someone You Know Now

Preface
The liquid biopsy is a novel technology which enables non-invasive diagnosis of cancer through
analysis of biological fluids such as blood, urine, and saliva, among others. The advent of liquid biopsy
has created several avenues to solve some of the pivotal challenges of the healthcare industry such
as lack of technologies enabling early diagnosis of cancer, treatment monitoring, and recurrence
monitoring, among others. The emergence of sedentary lifestyles, changing dietary habits, irregular
sleep patterns, and extravagant consumption of alcohol have resulted in enormous healthcare
burden. One of the leading medical conditions which contribute largely to the healthcare economic
burden in Latin America is cancer. According to Pan American Health Organization, the incidences
of cancer is expected to increase by 67% by 2030 as compared to 2012 in Latin America. The massive
economic burden of cancer is attributed to the rising prevalence of different types of cancer, recurring
need for diagnostic kits, and exorbitant cost of pharmaceutical products pertaining to cancer. The
lack of medical procedures enabling early detection and constant monitoring of cancer patients is the
key factor resulting in the rise of the number of cancer cases worldwide. Further, the growing geriatric
population has significantly necessitated the requirement for novel diagnostic procedures based on
minimal invasive procedures. Significant degree of research on molecular technologies, cancer
biomarkers, and biomarkers presence in body fluids has opened various pathways for the
development of a vital non-invasive diagnostic procedure as liquid biopsy.
Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of
molecular cancer biomarkers in the biological fluids. The test principally involves the usage of
samples of biological fluids, such as blood, urine, serum, and saliva, among others, and then the
analysis of the samples using different techniques, such as next generation sequencing (NGS) and
polymerase chain reaction (PCR) to detect the mutations known to cause cancer.
The following report titled “Latin America Liquid Biopsy Market” analyzes and discusses the
importance of minimally invasive diagnostic techniques, technological advancements involved with
the diagnostics, the factors promoting the growth of the market, and the challenges faced by the key
players in the market. It also covers the competitive landscape of the market, industry attractiveness,
growth potential, and market dynamics. The market has been segmented into “Biomarker”, “Clinical
Applications”, “Therapeutic Applications”, “Products and Services”, and “Country”. The report
presents the reader with an opportunity to unlock comprehensive insights with respect to the market
and helps in forming well-informed strategic decisions.
Key questions answered in the report:
 What are the key features of the liquid biopsy technology promoting its incorporation in
different clinical applications?
 What are key advantages of the liquid biopsy technology over tissue biopsy?
 How did the liquid biopsy market evolve and what is its scope in the future?

 What are the major market drivers, challenges, and opportunities in the Latin America liquid
biopsy market?
 Which are the leading companies dominating the Latin America liquid biopsy market?
 Which therapeutic application market would witness massive incorporation of the liquid biopsy
technology in the forecast period?
 Products based on which circulating biomarker are anticipated to witness massive rise in the
demand in the forecast period?
 How would the scope of clinical application of the liquid biopsy technology evolve in the
forecast period?
 What are investors’ perceptions about the Latin America liquid biopsy market? Also, who are
leading stakeholders of the market holding a significant share in market’s intellectual
property?
 What was the market value of the leading segments and sub-segments of the Latin America
liquid biopsy market?
 How will each segment of the Latin America liquid biopsy market grow during the forecast
period, and what will be the revenue generated by each of the segments by the end of 2025?
 How will the industry evolve during the forecast period 2019-2025?
 Which region will contribute to the highest rate of sales of the Latin America liquid biopsy
market during the forecast period?

Table of Content
Executive Summary………..…...………………………………………………14
1. Market Overview .................................................................................................... 26
1.1 Historical Trends.................................................................................................... 27
1.2 Comparative Analysis of Tissue Biopsy and Liquid Biopsy.............................. 28
1.3 Clinical Applications of Liquid Biopsy................................................................. 29
1.4 Trends for Liquid Biopsy ...................................................................................... 30
1.5 Latin America Liquid Biopsy Market Scenario.................................................... 31
2. Market Dynamics ................................................................................................... 32
2.1 Impact Analysis...................................................................................................... 33
2.2 Market Drivers........................................................................................................ 34
2.2.1 Potential of Liquid Biopsy.............................................................................. 34
2.2.2 Ability to Monitor Clonal Mutations................................................................ 34
2.2.3 Growing Prominence of Precision Medicine.................................................. 34
2.3 Market Restraints................................................................................................... 35
2.3.1 Uncertain Reimbursement and Regulatory Policies ...................................... 35
2.3.2 High Pricing Pressure ................................................................................... 35
2.3.3 Adoption of Traditional Diagnosis Practices.................................................. 36
2.4 Market Opportunities............................................................................................. 36
2.4.1 Development of Medication Package Deals.................................................. 36
2.4.2 Expansion into Emerging markets................................................................. 37
2.4.3 Scope of Liquid Biopsy for Intervention: Diagnosis of Non-Oncology
Disorders....................................................................................................... 37
3. Competitive Insights.............................................................................................. 38
3.1 Market Share Analysis........................................................................................... 38
3.2 Industry Attractiveness......................................................................................... 39
3.2.1 Bargaining Power of Suppliers...................................................................... 40
3.2.2 Bargaining Power of Buyer............................................................................ 41
3.2.3 Threat of New Entrants ................................................................................. 42
3.2.4 Threat of Substitute Products........................................................................ 43
3.2.5 Intensity of Competitive Rivalry..................................................................... 44
4. Latin America Liquid Biopsy Market (by Product Type)..................................... 46
4.1 Tests/Services........................................................................................................ 47

4.2 Kits and Consumables .......................................................................................... 48
4.3 Instruments ............................................................................................................ 49
5. Latin America Liquid Biopsy Market (by Circulating Biomarkers) .................... 51
5.1 Circulating Tumor DNA (ctDNA)........................................................................... 55
5.2 Circulating Tumor Cells (CTCs)............................................................................ 57
5.3 Cell-Free DNA (cfDNA) .......................................................................................... 58
5.4 Extracellular Vesicles and Others ........................................................................ 60
6. Latin America Liquid Biopsy Market (by Clinical Applications) ........................ 62
6.1 Treatment Monitoring............................................................................................ 63
6.2 Prognosis and Recurrence Monitoring................................................................ 64
6.3 Treatment Selection............................................................................................... 65
6.4 Diagnosis and Screening ...................................................................................... 66
7. Latin America Liquid Biopsy Market (by Therapeutic Applications)................. 67
7.1 Breast Cancer......................................................................................................... 69
7.2 Lung Cancer........................................................................................................... 71
7.3 Prostate Cancer ..................................................................................................... 74
7.4 Colorectal Cancer .................................................................................................. 75
7.5 Melanoma Cancer .................................................................................................. 77
7.6 Other Types of Cancer .......................................................................................... 79
7.7 Non-Oncology Application.................................................................................... 80
8. Latin America Liquid Biopsy Market (by Country).............................................. 82
8.1 Brazil....................................................................................................................... 83
8.2 Mexico..................................................................................................................... 86
8.3 Argentina ................................................................................................................ 88
8.4 Chile........................................................................................................................ 90
8.5 Colombia ................................................................................................................ 92
8.6 Rest-of-Latin America............................................................................................ 94
9. Company Profiles .................................................................................................. 95
9.1 Overview................................................................................................................. 95
9.2 Biocept, Inc. ........................................................................................................... 96
9.2.1 Company Overview....................................................................................... 96
9.2.2 Role of Biocept, Inc. in LATAM Liquid Biopsy Market ................................... 96
9.2.3 Overall Financials.......................................................................................... 97
9.2.4 Key Insights about Financial Health of the Company.................................... 98

9.2.5 SWOT Analysis............................................................................................. 99
9.3 Bio-Rad Laboratories, Inc. .................................................................................. 100
9.3.1 Company Overview..................................................................................... 100
9.3.2 Role of Bio-Rad Laboratories, Inc. in LATAM Liquid Biopsy Market ........... 100
9.3.3 Overall Financials........................................................................................ 101
9.3.4 Key Insights about Financial Health of the Company.................................. 104
9.3.5 SWOT Analysis........................................................................................... 105
9.4 Contextual Genomics Inc.................................................................................... 106
9.4.2 Role of Contextual Genomics Inc. in LATAM Liquid Biopsy Market............ 106
9.4.3 SWOT Analysis........................................................................................... 107
9.5 Epic Sciences, Inc................................................................................................ 108
9.5.2 Role of Epic Sciences, Inc. in the LATAM Liquid Biopsy Market................. 108
9.5.3 SWOT Analysis........................................................................................... 109
9.6 F. Hoffmann-La Roche AG .................................................................................. 110
9.6.2 Role of F. Hoffmann-La Roche AG in the LATAM Liquid Biopsy Market..... 110
9.6.5 SWOT Analysis........................................................................................... 116
9.7 Guardant Health, Inc............................................................................................ 117
9.7.2 Role of Guardant Health, Inc. in LATAM Liquid Biopsy Market................... 117
9.7.3 SWOT Analysis........................................................................................... 118
9.8 Illumina, Inc. ......................................................................................................... 119
9.8.2 Role of Illumina, Inc. in the LATAM Liquid Biopsy Market........................... 119
9.8.5 SWOT Analysis........................................................................................... 123
9.9 MDxHealth Inc. ..................................................................................................... 124
9.9.2 Role of MDxHealth, Inc. in the LATAM Liquid Biopsy Market...................... 124

9.9.4 Key Insights on the Financial Health of the Company................................. 126
9.9.5 SWOT Analysis........................................................................................... 127
9.10 Menarini Silicon Biosystems (Subsidiary of Menarini Group)......................... 128
9.10.2 Role of Menarini Silicon Biosystems in the LATAM Liquid Biopsy
Market ......................................................................................................... 128
9.10.3 SWOT Analysis........................................................................................... 130
9.11 MetaCell s.r.o........................................................................................................ 131
9.11.2 Role of MetaCell s.r.o in LATAM Liquid Biopsy Market............................... 131
9.11.3 SWOT Analysis........................................................................................... 132
9.12 Myriad Genetics, Inc............................................................................................ 133
9.12.2 Role of Myriad Genetics, Inc. in LATAM Liquid Biopsy Market ................... 133
9.12.4 Key Insights of the Financial Health of the Company.................................. 136
9.12.5 SWOT Analysis........................................................................................... 137
9.13 NeoGenomics Laboratories, Inc......................................................................... 138
9.13.2 Role of NeoGenomics Laboratories, Inc. in the LATAM Liquid Biopsy
Market ......................................................................................................... 138
9.13.5 SWOT Analysis........................................................................................... 142
9.14 Qiagen N.V............................................................................................................ 143
9.14.2 Role of Qiagen N.V. in the Liquid Biopsy Market ........................................ 143
9.14.5 SWOT Analysis........................................................................................... 148
9.15 Sysmex Inostics GmbH (Subsidiary of Sysmex Corporation) ......................... 149
9.15.2 Role of Sysmex Inostics GmbH in LATAM Liquid Biopsy Market................ 149
9.15.3 SWOT Analysis........................................................................................... 150

9.16 Thermo Fisher Scientific Inc............................................................................... 151
9.16.2 Role of Thermo Fisher Scientific Inc. in LATAM Liquid Biopsy Market........ 151
9.16.3 Financials.................................................................................................... 153
9.16.5 SWOT Analysis........................................................................................... 156
10. Research Scope and Methodology .................................................................... 157
10.1 Report Scope ....................................................................................................... 157

List of Figures
Figure: 1 Few Citations of Liquid Biopsy...........................................................................................16
Figure: 2 Latin America Market Drivers and Restraints ....................................................................17
Figure: 3 Latin America Liquid Biopsy Market, 2017-2025 ...............................................................18
Figure: 4 Latin America Liquid Biopsy Market (by Product Type), 2017 and 2025...........................19
Figure: 5 Latin America Liquid Biopsy Market (by Circulating Biomarkers), 2017 and 2025 ............20
Figure: 6 Latin America Liquid Biopsy Market (by Clinical Application), 2017-2025.........................21
Figure: 7 Latin America Liquid Biopsy Market (by Therapeutic Application), 2017-2025 .................22
Figure: 8 Latin America Liquid Biopsy Market (by Country), 2017-2025 ..........................................23
Figure: 9 Adoption Rate: Tissue Biopsy vs. Liquid biopsy................................................................24
Figure: 1.1 Different Types of Biomarkers in Liquid Biopsy..............................................................27
Figure: 1.2 Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker
Discovery ........................................................................................................................27
Figure: 1.3 Workflow Model of Tissue and Liquid Biopsy .................................................................29
Figure: 1.4 Clinical Applications of Liquid Biopsy .............................................................................30
Figure: 1.5 Latin America Liquid Biopsy Market, 2017-2025 ............................................................31
Figure: 2.1 Market Dynamics of LATAM Liquid Biopsy Market.........................................................32
Figure: 3.1 Market Share Analysis: Latin America Liquid Biopsy Market, 2016 and 2017 ...............38
Figure: 3.2 Porter’s Five Forces Analysis .........................................................................................40
Figure: 3.3 Bargaining Power of Suppliers: Overall Impact, 2014-2025...........................................41
Figure: 3.4 Bargaining Power of Buyers: Overall Impact, 2014-2025...............................................42
Figure: 3.5 Threat of New Entrant: Overall Impact, 2014-2025 ........................................................43
Figure: 3.6 Threat of Substitute Products: Overall Impact, 2014-2025.............................................44
Figure: 3.7 Intensity of Competitive Rivalry: Overall Impact, 2014-2025..........................................45
Figure: 4.1 Latin America Liquid Biopsy Market (by Circulating Biomarkers) ...................................46
Figure: 4.2 Liquid Biopsy Market (by Product Type), 2017-2025......................................................46
Figure: 4.3 Latin America Liquid Biopsy Market (by Tests/Services), 2017-2025 ............................47
Figure: 4.4 Latin America Liquid Biopsy Market (by Kits and Consumables), 2017-2025................49
Figure: 4.5 Latin America Liquid Biopsy Market (by Instruments), 2017-2025 .................................50
Figure: 5.1 Different Circulating Biomarkers.....................................................................................52
Figure: 5.2 Latin America Liquid Biopsy Market (by Circulating Biomarkers) ...................................53
Figure: 5.3 Latin America Liquid Biopsy Market (by Circulating Biomarker), 2017 and 2025...........54
Figure: 5.4 Latin America Liquid Biopsy Market (by ctDNA), 2017-2025..........................................55
Figure: 5.5 CTCs vs. ctDNA Analysis ...............................................................................................56
Figure: 5.6 Latin America Liquid Biopsy Market (by CTCs), 2017-2025...........................................57
Figure: 5.7 Latin America Liquid Biopsy Market (by cfDNA), 2017-2025..........................................59
Figure: 5.8 Latin America Liquid Biopsy Market (by Extracellular Vesicles and Others), 2017-2025
........................................................................................................................................60

Figure: 6.1 Latin America Liquid Biopsy Market (by Clinical Applications) .......................................62
Figure: 6.2 Liquid Biopsy Market (by Clinical Application), 2017-2025.............................................63
Figure: 6.3 Latin America Liquid Biopsy Market (by Treatment Monitoring), 2017-2025..................63
Figure: 6.4 Latin America Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2017-
2025 ................................................................................................................................64
Figure: 6.5 Latin America Liquid Biopsy Market (by Treatment Selection), 2017-2025....................65
Figure: 6.6 Latin America Liquid Biopsy Market (by Diagnosis and Screening), 2017-2025............66
Figure: 7.1 Latin America Liquid Biopsy Market (by Therapeutic Applications)................................68
Figure: 7.2 Latin America Liquid Biopsy Market (by Therapeutic Applications), 2017-2025.............68
Figure: 7.3 Types of Breast Cancer..................................................................................................70
Figure: 7.4 Latin America Liquid Biopsy Market (by Breast Cancer), 2017-2025.............................70
Figure: 7.5 Types of Lung Cancer ....................................................................................................72
Figure: 7.6 Latin America Liquid Biopsy Market (by Lung Cancer), 2017-2025 ...............................73
Figure: 7.7 Latin America Liquid Biopsy Market (by Prostate Cancer), 2017-2025..........................74
Figure: 7.8 Latin America Liquid Biopsy Market (by Colorectal Cancer), 2017-2025 .......................76
Figure: 7.9 Latin America Liquid Biopsy Market (by Melanoma Cancer), 2017-2025.......................78
Figure: 7.10 Latin America Liquid Biopsy Market (by Other Types of Cancer), 2017-2025..............79
Figure: 7.11 Latin America Liquid Biopsy Market (by Non-Oncology), 2017-2025...........................80
Figure: 8.1 Latin America Liquid Biopsy Market, 2017-2025 ............................................................82
Figure: 8.2 Latin America Liquid Biopsy Market (by Country), 2017-2025 .......................................83
Figure: 8.3 Brazil Liquid Biopsy Market, 2017-2025 .........................................................................84
Figure: 8.4 Brazil Liquid Biopsy Market (by Therapeutic Application), 2017-2025 ...........................85
Figure: 8.5 Mexico Liquid Biopsy Market, 2017-2025.......................................................................86
Figure: 8.6 Mexico: Liquid Biopsy Market (by Therapeutic Application), 2017-2025........................87
Figure: 8.7 Argentina Liquid Biopsy Market, 2017-2025...................................................................88
Figure: 8.8 Argentina: Liquid Biopsy Market (by Therapeutic Application), 2017-2025....................89
Figure: 8.9 Chile Liquid Biopsy Market, 2017-2025..........................................................................90
Figure: 8.10 Chile: Liquid Biopsy Market (by Therapeutic Application), 2017-2025 .........................91
Figure: 8.11 Colombia Liquid Biopsy Market, 2017-2025.................................................................92
Figure: 8.12 Colombia: Liquid Biopsy Market (by Therapeutic Application), 2017-2025 ..................93
Figure: 8.13 Rest-of-Latin America Liquid Biopsy Market, 2017-2025 .............................................94
Figure: 9.1 Shares of Key Company Profiles....................................................................................95
Figure: 9.2 Product Offerings............................................................................................................97
Figure: 9.3 Biocept, Inc.: Overall Financials, 2015-2017 ..................................................................97
Figure: 9.4 Biocept, Inc.: R&D Expense, 2015-2017 ........................................................................98
Figure: 9.5 Biocept, Inc.: SWOT Analysis.........................................................................................99
Figure: 9.6 Bio-Rad Laboratories, Inc.: Product Offerings..............................................................101
Figure: 9.7 Bio-Rad laboratories, Inc.: Overall Financials, 2015-2017 ...........................................101
Figure: 9.8 Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), 2015-2017 ..................102

Figure: 9.9 Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017.....................................103
Figure: 9.10 Bio-Rad Laboratories, Inc.: R&D Expense, 2015-2017 ..............................................104
Figure: 9.11 Bio-Rad Laboratories, Inc.: SWOT Analysis...............................................................105
Figure: 9.12 Contextual Genomics Inc.: SWOT Analysis ...............................................................107
Figure: 9.13 Epic Sciences, Inc.: Product Offerings .......................................................................108
Figure: 9.14 Epic Sciences, Inc.: SWOT Analysis ..........................................................................109
Figure: 9.15 F. Hoffmann-La Roche AG: Product Offerings ...........................................................111
Figure: 9.16 F. Hoffmann-La Roche AG: Overall Financials, 2015-2017 .......................................112
Figure: 9.17 F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017 ...............113
Figure: 9.18 F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics Sub-division), 2015-2017 .....114
Figure: 9.19 F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017..................................115
Figure: 9.20 F. Hoffmann-La Roche AG: R&D Expense, 2015-2017 .............................................115
Figure: 9.21 F. Hoffmann-La Roche AG: SWOT Analysis..............................................................116
Figure: 9.22 Guardant Health, Inc.: Product Offerings....................................................................117
Figure: 9.23 Guardant Health, Inc.: SWOT Analysis ......................................................................118
Figure: 9.24 Illumina, Inc.: Product Offerings..................................................................................120
Figure: 9.25 Illumina, Inc.: Overall Financials, 2015-2017..............................................................120
Figure: 9.26 Illumina, Inc.: Revenue (by Business Segment), 2015-2017......................................121
Figure: 9.27 Illumina, Inc.: Revenue (by Region), 2015-2017 ........................................................122
Figure: 9.28 Illumina, Inc.: R&D Expense, 2015-2017....................................................................122
Figure: 9.29 Illumina, Inc.: SWOT Analysis ....................................................................................123
Figure: 9.30 MDxHealth, Inc.: Product Offerings ............................................................................125
Figure: 9.31 MDxHealth, Inc.: Overall Financials, 2015-2017 ........................................................125
Figure: 9.32 MDxHealth, Inc.: R&D Expanse, 2015-2017 ..............................................................126
Figure: 9.33 MDxHealth, Inc.: SWOT Analysis...............................................................................127
Figure: 9.34 Menarini Silicon Biosystems, Inc.: Product Offerings .................................................129
Figure: 9.35 Menarini Silicon Biosystems, Inc.: SWOT Analysis ....................................................130
Figure: 9.36 Metacell s.r.o: SWOT Analysis ...................................................................................132
Figure: 9.37 Myriad Genetics, Inc.: Product Offerings....................................................................134
Figure: 9.38 Myriad Genetics, Inc.: Overall Financials, 2015-2017 ................................................134
Figure: 9.39 Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017 ........................135
Figure: 9.40 Myriad Genetics, Inc.: Revenue (by Region), 2015-2017...........................................136
Figure: 9.41 Myriad Genetics, Inc.: R&D Expense, 2015-2017 ......................................................136
Figure: 9.42 Myriad Genetics, Inc.: SWOT Analysis.......................................................................137
Figure: 9.43 NeoGenomics Laboratories, Inc.: Product Offerings ..................................................139
Figure: 9.44 NeoGenomics Laboratories, Inc.: Overall Financials, 2015-2017 ..............................140
Figure: 9.45 NeoGenomics Laboratories, Inc.: Revenue (by Business Segment), 2015-2017 ......141
Figure: 9.46 NeoGenomics Laboratories, Inc.: R&D Expense, 2015-2017 ....................................141

Figure: 9.47 NeoGenomics Laboratories, Inc.: SWOT Analysis.....................................................142
Figure: 9.48 Qiagen N.V.: Product Offerings ..................................................................................144
Figure: 9.49 Qiagen N.V.: Overall Financials, 2015-2017 ..............................................................145
Figure: 9.50 Qiagen N.V.: Revenue (by Business Segment), 2015-2017 ......................................146
Figure: 9.51 Qiagen N.V.: Revenue (by Region), 2015-2017.........................................................146
Figure: 9.52 Qiagen N.V.: R&D Expense, 2015-2017 ....................................................................147
Figure: 9.53 Qiagen N.V.: SWOT Analysis.....................................................................................148
Figure: 9.54 Sysmex Inostics GmbH: Product Offerings ................................................................149
Figure: 9.55 Sysmex Inostics GmbH: SWOT Analysis ...................................................................150
Figure: 9.56 Thermo Fisher Scientific Inc.: Product Offerings ........................................................152
Figure: 9.57 Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017 ....................................153
Figure: 9.58 Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017 ............153
Figure: 9.59 Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017...............................154
Figure: 9.60 Thermo Fisher Scientific Inc.: R&D Expense, 2015-2017 ..........................................155
Figure: 9.61 Thermo Fisher Scientific Inc.: SWOT Analysis...........................................................156
Figure: 10.1 Latin America Liquid Biopsy: Market Segmentation ...................................................157
Figure: 10.2 Latin America Liquid Biopsy Market Segmentation ....................................................159
Figure: 10.3 Primary Research.......................................................................................................160
Figure: 10.4 Secondary Research ..................................................................................................160
Figure: 10.5 Data Triangulation ......................................................................................................161
Figure: 10.6 Top-down Approach (Segment-wise Analysis)...........................................................162
Figure: 10.7 Bottom-up Approach (Segment-wise Analysis) ..........................................................163
Figure: 10.8 Assumptions and Limitations......................................................................................164
Figure: 10.9 Considered Factors for Data Prediction and Modelling ..............................................164

List of Tables
Table: 1.1 Tissue Biopsy vs. Liquid Biopsy.......................................................................................28
Table: 2.1 Impact Analysis................................................................................................................33
Table: 2.2 Governmental Initiatives for the Market Growth of Precision Medicine ...........................35
Table: 2.3 Incidence of Leading Cancer Types (by Country), 2018 and 2040..................................37
Table: 7.1 Breast Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030 .....71
Table: 7.2 Lung Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030........73
Table: 7.3 Prostate Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030 ..75
Table: 7.4 Colorectal Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
........................................................................................................................................76
Table: 7.5 Melanoma Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
........................................................................................................................................78
Table: 7.6 Ovarian Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030 ...79
Table: 7.7 Stomach Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030..80
Table: 8.1 Healthcare Expenditure (US$ per head) in Latin American Countries, 2015-2017 .........82
Table: 8.2 Brazil: Prevalence of Different Types of Cancer, 2018-2030...........................................84
Table: 8.3 Mexico: Prevalence of Different Types of Cancer, 2018-2030 ........................................86
Table: 8.4 Argentina: Prevalence of Different Types of Cancer, 2018-2030 ....................................88
Table: 8.5 Chile: Prevalence of Different Types of Cancer, 2018-2030............................................91
Table: 8.6 Colombia: Prevalence of Different Types of Cancer, 2018-2030.....................................93

BIS Research Offerings:
We’re on a mission to harness the potential of disruptive technologies to make businesses thrive in
today’s digital age. With a vision to be a leading and a preferred knowledge partner for corporates
and institutions worldwide and assist with market intelligence in the area of emerging technologies,
advisory, and other innovative solutions.
Know More Know More
Know More
Know More

Disclaimer
BIS Research provides valuable market intelligence to an exclusive group of customers in
response to orders. The report is licensed only for the customer's internal use and is subject
to restrictions set henceforth. This document and its contents are confidential and may not
be further distributed, published, or reproduced, in whole or in part, by any medium or in any
form for any purpose, without the expressed written consent of BIS Research. The customer
will neither disclose the contents of the report, whether directly in any media or indirectly
through the incorporation in a database, marketing list, report or otherwise; use or permit the
use of information to generate any statistical or other information that is or will be provided
to third parties; nor voluntarily produce the information in any legal proceedings.
Market reports are based on the expectations, estimates, and projections, as of the date such
information is available at. Recommendations, if any, contained in this report may or may not
be suitable for all investors or businesses. The market conclusions drawn are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by
BIS Research as of the date of such statements, are inherently subject to market fluctuations
as well as business, economic, and competitive uncertainties and contingencies.
For more details regarding permission, please contact us:
Email: healthcare@bisresearch.com
Tel: +1 510 404 8135

BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: info@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

Latin America Liquid Biopsy Market Analysis and Forecast 2019-2025

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Latin America Liquid Biopsy Market Analysis and Forecast 2019-2025

Similar to Latin America Liquid Biopsy Market Analysis and Forecast 2019-2025 (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Latin America Liquid Biopsy Market Analysis and Forecast 2019-2025